January/February #151 : Earlier HIV Meds? - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Out On A Limb

Your Money or Your Life




The Sinus Monologues

Expert Opinion

Earlier HIV Meds?

HIV Treatment Guidelines Revised Again

Tea Time

Check My Meds

HIV-Med Pipeline Update

Complaint Department

Med Alert

Share the Wealth

Decreased Counts

Energy Savers

Sexual Healing

Make Those Doc Visits Count




Seeking Sisterhood

Forgotten No More

Is AIDS a Riot?

This Boy’s Life

Resistance Is Futile




Editor's Letter - Jan/Feb 2009

Letters - Jan/Feb 2009

Bear With Him

NAPWA/TAEP HIV/AIDS POLICY REPORT - Jan/Feb 2009



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


Scroll down to comment on this story.


email print

January / February 2009


Earlier HIV Meds?

by Laura Whitehorn

Research suggests starting treatment with a higher CD4 count.

Based on evidence of increasing health problems among positive people with relatively high CD4s who are not yet on HIV meds, the U.S. treatment guidelines raised the recommended starting point of drug therapy from 200 to 350 CD4 cells a year ago. But researchers at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last August suggested a higher starting point: 500.

A review of records of 8,374 positive people in the United States and Canada from 1996 to 2006 found that the risk of dying from any cause was 70 percent lower for people who started meds with CD4 counts between 351 and 500 than for those who started with counts between 200 and 350. These results, reported by researchers at the University of Washington in Seattle, echo other large HIV studies suggesting that HIV meds protect against health problems seemingly independent of HIV—such as heart disease and cancer.

It’s not yet clear whether earlier treatment raises the risk of side effects or drug resistance. While current treatment guidelines still say to start at 350, a change could be coming.     

Search: early treatment, CD4, Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, University of Washington


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         

[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    Hillcrester
    Ramona
    California


    juliar33
    brooklyn
    New York


    jimmy807
    San Antonio
    Texas


    thebake
    Sioux Falls
    South Dakota
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.